Related Experiment Video

Updated: Aug 7, 2026

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

Renin-angiotensin system inhibition improves coronary flow reserve in hypertension

E D Frohlich1

  • 1Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA.

Journal of Cardiovascular Pharmacology
|June 8, 2001
PubMed

Insights

Combining an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin-II receptor blocker significantly improved coronary flow reserve in hypertensive rats. This combination therapy reduced cardiovascular mass and improved hemodynamics, suggesting potential benefits for hypertensive patients.

Area of Science:

  • Cardiovascular Physiology
  • Pharmacology

Background:

  • Angiotensin II significantly impacts arterial pressure, hemodynamics, and cardiovascular structure, worsening hypertensive disease.
  • Reduced coronary blood flow and flow reserve are key indicators of arteriolar disease and endothelial dysfunction in hypertension, increasing cardiovascular risk.

Purpose of the Study:

  • To investigate the effect of renin-angiotensin system inhibition on impaired coronary flow reserve in spontaneously hypertensive rats.
  • To evaluate the efficacy of a combination therapy with an ACE inhibitor and an angiotensin-II type 1 receptor blocker.

Main Methods:

  • Spontaneously hypertensive rats were treated for 12 weeks with equidepressor doses of an ACE inhibitor and an angiotensin-II receptor blocker combination.
  • Coronary flow reserve was assessed, along with cardiovascular mass, systemic hemodynamics, and ventricular metabolic demands.

Main Results:

  • The combination therapy markedly improved coronary flow reserve to levels observed in normotensive rats.
  • Treatment significantly diminished cardiovascular mass and improved systemic hemodynamics and ventricular metabolic demands.
  • Individual renin-angiotensin system inhibitors also improved coronary flow reserve, but the combination therapy showed superior effects.

Conclusions:

  • Combination therapy with an ACE inhibitor and an angiotensin-II receptor blocker is highly effective in restoring coronary flow reserve in hypertension.
  • This therapeutic approach offers potential benefits for patients with hypertension and hypertensive heart disease, warranting further clinical investigation.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...